The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 |
doi: 10.3389/fimmu.2024.1434737
This article is part of the Research Topic Clinical Implementation of Precision Oncology Data to Direct Individualized and Immunotherapy-Based Treatment Strategies View all 4 articles
Causal effect of thyroid cancer on secondary primary malignancies: findings from the UK Biobank and FinnGen cohorts
Provisionally accepted- 1 Shanghai Tenth People's Hospital, Tongji University, Shanghai, China
- 2 Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
- 3 Yueyang Hospital, Yueyang, Hunan Province, China
Background: Existing epidemiological data indicated a correlation between thyroid cancer (THCA) and the risk of secondary primary malignancies (SPMs). However, the correlation does not always imply causality.The Mendelian randomization (MR) analyses were performed to investigate the causal relationships between THCA and SPMs based on international multicenter data. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated. The Cancer Genome Atlas (TCGA) was used to explore potential mechanisms shared by THCA and bladder cancer (BLCA).Results: Summary datasets of genome-wide association studies (GWAS) on 30 types of cancers were obtained from the United Kingdom Biobank (UKB) and FinnGen database. Meta-analysis of the UKB and FinnGen results revealed that THCA was significantly positively correlated with BLCA (OR = 1.140; 95% CI, 1.072-1.212; P < 0.001). Four genes, including WNT3, FAM171A2, MLLT11, and ULBP1, were identified as key genes shared by both TCHA and BLCA. Correlation analysis indicated that THCA may increase the risk of secondary BLCA through augmentation of N2 neutrophil infiltration.Conclusions: This study showed that THCA was causally related to BLCA. It is recommended to conduct more rigorous screenings for BLCA during the follow-up of THCA patients.
Keywords: thyroid cancer, GWAS, Mendelian randomization, Bladder cancer, SNP
Received: 18 May 2024; Accepted: 10 Sep 2024.
Copyright: © 2024 Wang, Rixiati, Jia, Xu, Yin, Huang, Dai and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Youlutuziayi Rixiati, Huashan Hospital, Fudan University, Shanghai, Shanghai Municipality, China
Zhiqiang Yin, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China
Junwen Huang, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China
Yun Zhang, Shanghai Tenth People's Hospital, Tongji University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.